Meeting Information - Chengdu Huasheng Technology Group Co., Ltd. will hold its first extraordinary general meeting of shareholders in 2025 on August 19, 2025, combining on-site voting and online voting [1][2] - The on-site meeting will take place at the company's research complex located at No. 1168 Shuxin Avenue, Chengdu High-tech Zone (West) [3] Voting Procedures - Shareholders can vote through the Shenzhen Stock Exchange trading system and the internet voting system during the specified voting times [2][6] - Shareholders must choose one voting method: on-site voting, trading system voting, or internet voting [2][5] - The voting results for small and medium investors will be counted separately from those of directors, supervisors, senior management, and shareholders holding more than 5% of shares [5] Registration and Attendance - Eligible shareholders or their agents must present identification and proof of shareholding to register for the meeting [6] - Proxy representatives must also provide a power of attorney along with their identification [6] Proposal Details - The meeting will review specific proposals, including the proposal for the public transfer of 51% equity in Tibet Kangyu [12] - The proposals have been approved by the company's 13th Board of Directors at its 23rd meeting [5] Contact Information - For inquiries, shareholders can contact Liu Qing or Sun Jia at the provided phone number and email [6]

Transaction Overview - The company plans to publicly transfer 51% equity of its subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., to focus resources on core business and enhance profitability [1][2] - The initial transfer price is set at RMB 63.78 million based on an asset appraisal [1][6] Financial Performance of the Target Company - The target company's total assets increased from RMB 12,287.27 million to RMB 15,871.39 million over the last year [5] - Total liabilities rose from RMB 7,519.00 million to RMB 11,392.73 million [5] - Net profit for the last audited year was RMB 1,678.43 million, up from RMB 289.61 million [5] Asset Valuation - The valuation of the 51% equity stake is based on an appraisal conducted by Walker (Beijing) International Asset Appraisal Co., Ltd., using both asset-based and income approaches [6] - The assessed value of the target company's total equity is RMB 125.06 million, with an increase of RMB 77.38 million, representing a growth rate of approximately 164.5% [6] Approval Process - The proposal for the equity transfer requires approval from the company's shareholders' meeting before execution [2][8] - The independent directors and supervisory board have expressed support for the transaction, confirming that it aligns with the company's strategic goals and does not harm shareholder interests [7][8] Future Implications - If the transaction is completed, the target company will no longer be included in the company's consolidated financial statements [6] - The transaction is seen as a necessary step for optimizing the company's investment structure and enhancing its operational capabilities [8]

Group 1 - The company Chengdu Huasheng Technology Group Co., Ltd. acquired 51% equity of Tibet Kangyu Pharmaceutical Co., Ltd. for RMB 51 million, making it a subsidiary included in the consolidated financial statements [1][2] - The transferor committed to achieving net profits of no less than RMB 15 million, RMB 20 million, and RMB 25 million for the years 2023 (August-December), 2024, and 2025 respectively [2][3] - If the net profit falls below 60% of the promised amount, the transferor must compensate the company in cash based on a specific formula [2][3] Group 2 - In 2024, Tibet Kangyu's net profit was RMB 16.7843 million, which is below the promised RMB 20 million, resulting in a cash compensation of RMB 6.5601 million from the transferor [4] - The performance compensation for the 2024 fiscal year has been fully executed [4]

Core Viewpoint - Chengdu Huashen Technology Group Co., Ltd. plans to transfer its 51% stake in Tibet Kangyu Pharmaceutical Co., Ltd., and an asset evaluation report has been prepared to assess the market value of the entire equity of Tibet Kangyu Pharmaceutical as of April 30, 2025 [1][4][17]. Group 1: Evaluation Purpose and Scope - The purpose of the asset evaluation is to provide a market value reference for the transfer of the 51% stake in Tibet Kangyu Pharmaceutical, which has been approved by the management of Chengdu Huashen Technology Group [4][15]. - The evaluation object includes all equity of Tibet Kangyu Pharmaceutical related to the 51% stake being transferred, and the evaluation scope encompasses all assets and liabilities reported by Tibet Kangyu as of the evaluation benchmark date [5][17]. Group 2: Financial Overview - As of April 30, 2025, the book value of the equity of Tibet Kangyu Pharmaceutical included in the evaluation is 47.6827 million RMB [5][18]. - The total assets of Tibet Kangyu Pharmaceutical as of the evaluation date are 122.8727 million RMB, with current assets amounting to 121.7788 million RMB and non-current assets at 1.0940 million RMB [18]. - The total liabilities amount to 75.1900 million RMB, with current liabilities at 74.0933 million RMB and non-current liabilities at 1.0967 million RMB [18]. Group 3: Financial Performance - The operating income for the year 2022 was 367.0327 million RMB, with a net profit of 103.825 million RMB [14]. - For the year 2023, the operating income was 368.7942 million RMB, and the net profit was 174.047 million RMB [14]. - The projected operating income for the first four months of 2025 is 220.4142 million RMB, with a net profit of 28.961 million RMB [14].

Audit Opinion - The audit report states that the financial statements of Tibet Kangyu Pharmaceutical Co., Ltd. fairly reflect its financial position as of December 31, 2024, and April 30, 2025, in accordance with accounting standards [2][3]. Company Overview - Tibet Kangyu Pharmaceutical Co., Ltd. was established on March 18, 2015, with a registered capital of RMB 10 million, fully paid [5]. - The company operates in the wholesale industry, primarily engaged in the sale of pharmaceuticals and medical devices, along with various other products [5]. Financial Reporting Basis - The financial statements are prepared based on the going concern assumption, indicating that the company has the ability to continue its operations for at least the next 12 months [6]. - The financial statements comply with the requirements of the accounting standards, providing a true and complete reflection of the company's financial status, operating results, and cash flows [6]. Accounting Policies and Estimates - The company uses the perpetual inventory system for its inventory management, valuing inventory at actual cost upon acquisition [22]. - The company recognizes financial assets and liabilities based on their classification, including those measured at amortized cost and those measured at fair value [10][12]. Financial Instruments - Financial assets are classified based on the business model for managing them and their contractual cash flow characteristics [6][10]. - The company applies the expected credit loss model for impairment accounting, assessing credit risk based on historical experience and current conditions [16][19]. Long-term Investments - Long-term equity investments are accounted for using the cost method for subsidiaries and the equity method for joint ventures and associates [26][27]. - The company evaluates its long-term investments based on the fair value of the underlying assets and adjusts the carrying amount accordingly [24][28].

Core Viewpoint - Huasheng Technology announced the approval of multiple proposals, including the performance commitment completion status of Tibet Kangyu Pharmaceutical Co., Ltd. for the year 2024 during the 23rd meeting of its 13th Board of Directors [2] Summary by Relevant Sections - Company Announcement - Huasheng Technology released an announcement on the evening of August 1, stating that its Board of Directors approved several proposals [2] - One of the key proposals discussed was related to the performance commitment completion status of Tibet Kangyu Pharmaceutical for the year 2024 [2]

Group 1 - The company announced the approval of the performance commitment completion for Tibet Kangyu Pharmaceutical Co., Ltd. for the year 2024 [2] - The company plans to publicly transfer 51% equity stake in Tibet Kangyu Pharmaceutical [2]

Group 1 - The company, Huasheng Technology, announced that it will hold its first extraordinary general meeting of shareholders on August 19, 2025 [1] - The agenda for the meeting includes the proposal to publicly transfer 51% equity of Tibet Kangyu [1]

Group 1 - The company, Huasheng Technology (000790.SZ), announced the intention to transfer 51% equity of its subsidiary, Tibet Kangyu, to focus resources on core business and enhance profitability and competitiveness [1] - The transfer will be conducted through a public listing at the Southwest United Property Exchange, with a starting price based on the asset evaluation agency's assessment, set at RMB 63.7806 million [1]

华神科技（000790）(000790.SZ)公告，公司拟通过公开挂牌转让公司控股子公司西藏康域药业有限公 司(简称"西藏康域")51%股权，挂牌底价为6378.06万元。公司本次股权转让将在西南联合产权交易所以 公开挂牌转让方式进行，交易受让方尚不能确定。 ...